The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

NCT03192618 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

290

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: adjuvant transarterial chemoinfusion (TAI)
DRUG: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

Sponsor

Sun Yat-sen University